Causal links between gut microbiota, metabolites, and diffuse large B-cell lymphoma: Evidence from a Mendelian...

Area of Science:

• Microbiome research
• Oncology
• Metabolomics

Background:

• The exact link between gut microbiota, their metabolites, and diffuse large B-cell lymphoma (DLBCL) is not fully understood.
• Investigating these connections is crucial for understanding DLBCL pathogenesis.

Purpose of the Study:

• To explore potential causal relationships between gut microbial composition, their metabolites, and the risk of developing DLBCL.
• To identify specific microbial taxa and metabolites that may influence DLBCL development.

Main Methods:

• Utilized Mendelian randomization (MR) analysis with large-scale genetic data for gut microbiota (MiBioGen) and DLBCL (FinnGen).
• Incorporated microbiota-derived metabolite data from TwinsUK and KORA studies.
• Performed inverse-variance weighting (IVW) as the primary method, with sensitivity analyses and reverse MR for robustness.

Main Results:

• Identified specific gut bacteria associated with altered DLBCL risk: Bilophila (increased risk), Alistipes and Ruminococcaceae UCG011 (reduced risk).
• Found causal links between DLBCL risk and specific metabolites: indolepropionate (reduced risk) and 7-alpha-hydroxy-3-oxo-4-cholestenoate (increased risk).
• Reverse MR analysis indicated potential bidirectional relationships, with Anaerofilum positively associated with DLBCL risk.

Conclusions:

• This Mendelian randomization study provides evidence for a causal influence of specific gut microbial taxa on DLBCL risk.
• Findings suggest that certain gut microbiota-derived metabolites may also play a causal role in the development of DLBCL.